Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia—Overview, Evolution, and Regulations Assessment
Open Access
- 24 April 2016
- journal article
- research article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2016, 1-12
Abstract
The development of biological products has experienced continuous growth over the past three decades. The expiration of patent protection for many biological medicines has led to the development of biosimilars in many countries around the world. This paper reviews the literature on biosimilar drugs and covers their therapeutic status, clinical trials, approved biosimilars, and regulatory guidelines in Japan, South Korea, and Malaysia. The literature suggests that biosimilars are comparable but not identical to the reference product. They are not a generic version of an innovative product and do not ensure therapeutic equivalence. Biosimilars present more challenges than conventional generics and their marketing approval is also much more complicated. Guidelines for biosimilars were published in Japan in July 2009 by the Ministry of Health, Labour and Welfare (MHLW), in South Korea in March 2009 by the Ministry of Food and Drug Safety (MFDS), and in Malaysia in July 2008 by the National Pharmaceutical Control Bureau (NPCB).Keywords
This publication has 9 references indexed in Scilit:
- Korean regulations for biosimilarsGenerics and Biosimilars Initiative Journal, 2015
- Regulatory and clinical considerations for biosimilar oncology drugsThe Lancet Oncology, 2014
- The advent of biosimilars: challenges and risksSwiss Medical Weekly, 2014
- Innovation and Competition: Will Biosimilars Succeed?: The creation of an FDA approval pathway for biosimilars is complex and fraught with hazard. Yes, innovation and market competition are at stake. But so are efficacy and patient safety.2012
- NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety PerspectivesJournal of the National Comprehensive Cancer Network, 2011
- Regulatory guideline for biosimilar products in KoreaBiologicals, 2011
- Quality, safety and efficacy of follow-on biologics in JapanBiologicals, 2011
- Industry views of biosimilar development in JapanHealth Policy, 2009
- (Re)defining biopharmaceuticalNature Biotechnology, 2008